Get started
Author

Chris Barber

Observed names: Barber, C.G., C. BARBER, C. Barber, C. G. BARBER, C.G. Barber, Chris G Barber, Chris G. Barber, Christopher Barber, Christopher G Barber, Christopher G. Barber
ORCID: 0000-0003-4220-1137
Observed ORCID: 0000-0003-4220-1137
OpenAlex ID: A5083785539
Addressing toxicity risk when designing and selecting compounds in early drug discovery
2014 · Matthew D. Segall, Chris Barber · Drug Discovery Today · 185
Improvement of quantitative structure–activity relationship (QSAR) tools for predicting Ames mutagenicity: outcomes of the Ames/QSAR International Challenge Project
2018 · Masamitsu Honma, Airi Kitazawa, et al. · Mutagenesis · 152
Applicability domain: towards a more formal definition
2016 · T. Hanser, C. Barber, et al. · SAR and QSAR in environmental research · 142
Synthetic applications of metallate rearrangements
1990 · P. Kocienski, Christopher Barber · Pure and Applied Chemistry · 120
PDF
Establishing best practise in the application of expert review of mutagenicity under ICH M7
2015 · Chris Barber, Alexander Amberg, et al. · Regulatory Toxicology and Pharmacology · 85
Selective Urokinase-Type Plasminogen Activator Inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines
2007 · Paul V. Fish, Christopher G. Barber, et al. · Journal of Medicinal Chemistry · 63
Evaluation of a statistics-based Ames mutagenicity QSAR model and interpretation of the results obtained
2015 · Chris Barber, Alex Cayley, et al. · Regulatory Toxicology and Pharmacology · 49
Self organising hypothesis networks: a new approach for representing and structuring SAR knowledge
2014 · Thierry Hanser, Chris Barber, et al. · Journal of Cheminformatics · 48
PDF
Data-driven federated learning in drug discovery with knowledge distillation
2025 · Thierry Hanser, Ernst Ahlberg, et al. · Nature Machine Intelligence · 43
Predicting skin sensitisation using a decision tree integrated testing strategy with an in silico model and in chemico/in vitro assays
2016 · Donna S. Macmillan, Steven J. Canipa, et al. · Regulatory Toxicology and Pharmacology · 41
Novel Selective Inhibitors of Neutral Endopeptidase for the Treatment of Female Sexual Arousal Disorder. Synthesis and Activity of Functionalized Glutaramides
2006 · David C. Pryde, Graham N. Maw, et al. · Journal of Medicinal Chemistry · 38
Assessment and Reproducibility of Quantitative Structure–Activity Relationship Models by the Nonexpert
2018 · Mukesh Patel, Martyn L. Chilton, et al. · Journal of Chemical Information and Modeling · 37
PDF
Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-Isoquinolinylguanidines
2004 · Christopher G. Barber, Roger P. Dickinson, et al. · Bioorganic & Medicinal Chemistry Letters · 37
A consortium-driven framework to guide the implementation of ICH M7 Option 4 control strategies
2017 · Chris Barber, Vincent Antonucci, et al. · Regulatory Toxicology and Pharmacology · 36
The importance of expert review to clarify ambiguous situations for (Q)SAR predictions under ICH M7
2020 · Robert S. Foster, Adrian Fowkes, et al. · Genes and Environment · 35
PDF
Controlling a Cohort: Use of Mirabilis-Based Purge Calculations to Understand Nitrosamine-Related Risk and Control Strategy Options
2020 · Michael J. Burns, Andrew Teasdale, et al. · Organic Process Research & Development · 34
Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses
2018 · Alexander Amberg, Roxanne V. Andaya, et al. · Regulatory Toxicology and Pharmacology · 33
A Method for the Synthesis of 6-(Trimethylstannyl)-3,4-dihydro-2H-pyrans from δ-Valerolactones
1991 · Christopher Barber, Krzysztof Jarowicki, et al. · Synlett · 33
Distinguishing between expert and statistical systems for application under ICH M7
2017 · Chris Barber, Thierry Hanser, et al. · Regulatory Toxicology and Pharmacology · 32
Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines
2002 · Christopher G Barber, Roger P Dickinson, et al. · Bioorganic & Medicinal Chemistry Letters · 32
A Novel Series of Potent and Selective PDE5 Inhibitors with Potential for High and Dose-Independent Oral Bioavailability
2006 · Charlotte M. N. Allerton, Christopher G. Barber, et al. · Journal of Medicinal Chemistry · 31
The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics
2011 · David J. Rawson, Stephen Ballard, et al. · Bioorganic & Medicinal Chemistry · 29
Characterisation of data resources forin silicomodelling: benchmark datasets for ADME properties
2017 · K.R. Przybylak, J.C. Madden, et al. · Expert Opinion on Drug Metabolism & Toxicology · 28
PDF
Value of shared preclinical safety studies – The eTOX database
2014 · Katharine Briggs, Chris Barber, et al. · Toxicology Reports · 28
PDF
CCR5 antagonists for the treatment of HIV.
2004 · Chris G Barber · PubMed · 28
Works count: 63
Citation count: 1,697
H-index: 26
I10-index: 39
Year
Topic
Type